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Progress has been made in understanding the genetics and molecular biology of frontotemporal dementia (FTD).
Targets for intervention have been identified, therapies are being developed, and clinical trials are advancing. A
major challenge for FTD research is that multiple underlying pathologies can be associated with heterogeneous
phenotypes. The neuropsychological profiles associated with FTD spectrum disorders often include executive
dysfunction, language impairments and behavioral disturbance. Behavioral variant FTD is characterized by an initial
presentation of changes in personality, behavior and/or emotion, which are often difficult to objectively capture
using traditional neuropsychological measures. The two principal language variants of FTD are Progressive
Nonfluent Aphasia (PNFA) with predominant agrammatic/non-fluent impairments and Semantic Dementia (SD)
with semantic impairments and visual agnosia. Selection of appropriate endpoints for clinical trials is critical to
ensure that the measures are adequately sensitive to detect change, yet specific enough to isolate signal from
noise, and acceptable to regulatory agencies. Given the anticipated potential for small effect sizes, measures must
be able to identify small incremental changes over time. It is also imperative that the measures provide adequate
coverage of the constructs or behaviors of interest. Selected outcome measures should be suitable for repeat
administration, yet relatively robust to practice effects to ensure that observed changes reflect true signal variance
and not residual effects due to repeated measurement or poor reliability. To facilitate widespread adoption as an
endpoint, measures should be readily accessible. We provide several examples of potential global, composite, and
individual cognitive measures, as well as behavioral measures promising for FTD trials. Development and
application of appropriate trial outcomes is critically important to success in advancing new treatments for FTD
patients.
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ally diverse neurodegenerative disease that rivals the preva-
lence of Alzheimer’s disease (AD) in adults younger than
65 [1]. A major challenge for FTD research is that there are
multiple underlying pathologies [2,3], and any of the identi-
fied pathologies can be associated with heterogeneous phe-
notypes depending upon the lesion type, load, and
distribution [4,5]. Classifications of FTD are evolving based
on genotype, protein abnormality, and phenotype. The
neuropsychological profile associated with FTD spectrum
disorders often includes executive dysfunction and lan-
guage impairments. Behavioral variant frontotemporal de-
mentia (bvFTD) is characterized by an initial presentation* Correspondence: millerj4@ccf.org
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unless otherwise stated.of changes in personality, behavior and/or emotion which
are often difficult to objectively capture using traditional
neuropsychological measures. There are two principal lan-
guage variants associated with FTD: Primary Progressive
Nonfluent Aphasia (PPNA) with predominant agrammatic/
non-fluent impairments or Semantic Dementia (SD) with
fluent verbal output and semantic impairments [6]. A third
language variant, Logopenic progressive aphasia, is occa-
sionally associated with FTD, although most cases with
aphasia of the logopenic type are due to AD [6].
Improved understanding of the neurobiology of FTD
has led to the identification of candidate therapies that ad-
dress the underlying pathophysiology associated with this
group of disorders [7]. Clinical trials are anticipated as
promising agents are introduced to human populations to
assess efficacy. Given the phenotypic diversity of FTD,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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challenging and making good choices is critical to ensure
that the trial measures are adequately sensitive to detect
change, yet specific enough to isolate signal from noise,
and acceptable to regulatory agencies (i.e., Food and Drug
Administration, FDA; European Medicines Agency, EMA).
The primary aim of this paper is to discuss consider-
ations for identification and selection of appropriate
cognitive and behavioral endpoints (e.g., domains of
function) for use in clinical trials. It is not our intent to
be prescriptive about specific measures or endpoints to
employ, but to generate recommendations and identify
critical factors to consider during trial planning to facili-
tate selection of neuropsychological endpoints. There
are a number of biomarkers that should also be consid-
ered for use in randomized clinical trials (RCTs) for
FTD, however, discussion of such measures is beyond
the scope and aims of this paper. Here, we restrict our
emphasis to the cognitive and behavioral phenotypes,
relevant to selecting outcomes for RCTs.FDA Recommended Outcomes in RCTs
In order to promote uniformity across drug development
for dementia disorders, the United States FDA mandates
several essential outcome types that must be included in
dementia-related trials. Although the FDA does not have
requirements for specific tests or measures that need to
be included, nonbinding recommendations are made re-
garding the domains to be assessed. In AD trials --- which
function as a guide to how to conduct FTD trials --- the
FDA requires dual outcomes: a measure of the core cogni-
tive features of the disorder and a global or functional
measure to determine the clinical meaningfulness of any
therapeutic benefit [8]. Often based on clinician ratings,
global measures attempt to provide an overall quantitative
estimate of cognition, behavior, and daily functioning and
are frequently used as a co-primary endpoint [9]. Exam-
ples of commonly used global measures in AD trials in-
clude the Clinical Dementia Rating (CDR) [10] and the
Clinicians’ Interview-Based Impression of Change (CIBIC)
[9]. An alternative indicator of clinical meaningfulness is
the use of a measure of activities of daily living such as the
Alzheimer’s Disease Cooperative Study (ADCS) Activities
of Daily Living (ADL) scale [11] or the Disability Assess-
ment for Dementia (DAD) [12].
These global or functional measures are complemented
by a measure of the core cognitive components of the de-
mentia syndrome. In AD, the Alzheimer’s Disease Assess-
ment Scale - Cognitive Portion (ADAS-Cog) [13] is the
most commonly used neuropsychological assessment. This
tool, however, lacks executive measures, emphasizes cap-
ture of the memory impairment characteristic of AD and
does not explore language in depth, limiting its usefulnessfor FTD clinical trials. Alternative measures sensitive to the
specific abnormalities found in FTD are needed.
Secondary outcome measures are commonly used in
dementia trials to assess behavioral [14] and economic
outcomes [15]. These secondary outcomes provide add-
itional insight into drug effects but are not included in
the package insert description of an approved agent.
Although FTD has known and identifiable pathologies
and several potential biomarkers [16], use of biomarkers
as a surrogate for clinical benefit is currently not avail-
able in dementia syndromes [17]. Until such evidence
exists, measures of cognition will remain the central
marker of change and clinical benefit.
Current summary of randomized clinical trials in
FTD
There have been relatively few randomized clinical trials
(RCTs) in FTD, and those that have been conducted have
been small and often inconclusive, particularly with regard
to cognition. A review of RCTs published in the last decade
indicates that several existing pharmacological interven-
tions may be beneficial for reducing behavioral disturbances
in FTD, however, none of the reviewed studies yielded any
benefit for improving cognition [18] and some have shown
undesirable effects [7,19]. A summary of the endpoints re-
ported in the published trials is presented in Table 1.
Among the reviewed trials, the Clinical Global Impres-
sion (CGI) and its subscales specific to change (CGI-C),
improvement (CGI-I) and severity (CGI-S) was used in 3
trials [7,22,25], and the CIBIC with caregiver input
(CIBIC+) was used in one as a global measure [19]. As-
sessment of cognition was much more variable across
the trials, with little evidence of uniformity in either do-
main coverage or assessment approach. Memory and ex-
ecutive functioning were the most commonly assessed
domains. Three studies assessed episodic memory expli-
citly via subscales of composite batteries (e.g., Dementia
Rating Scale; DRS [27]; Repeatable Battery for the As-
sessment of Neuropsychological Status; RBANS [28])
and six of nine studies evaluated some component of ex-
ecutive functioning, though there was no standard ap-
proach. The Mini-Mental Status Exam (MMSE) [29] was
the most frequently administered cognitive measure,
with use in five of nine trials. Several studies employed
a battery of cognitive tests, including the Cambridge
Neuropsychological Test Automated Battery (CANTAB)
and the DRS, which were the second most frequently used
measures, appearing in two trials each [19,21,23,25]. The
RBANS was employed in one trial [24]. The diversity of
approaches observed in these trials suggests that a consen-
sus has not been reached on how best to assess FTD
spectrum disorders in RCTs.
Much greater uniformity was apparent across trials with
regard to behavioral endpoints, and most trials employed
Table 1 Summary of published endpoints in randomized controlled trials in frontotemporal dementia
Study Sample size Global endpoints Cognitive endpoints Behavioral endpoints
Moretti, R. et al. [20] 16 --- MMSE, Ten Point Clock Test, Proverb
Interpretation Tasks, Stroop Test
NPI, CIRS, CSDD, BEHAVE-AD
Deakin, J.B. et al. [21] 10 --- CANTAB*, Verbal fluency, Digit Span NPI, CBI
Lebert, F. [22] 26 CGI-I MMSE NPI
Rahman, S. [23] 8 --- NART, MMSE, CANTAB**, Cambridge Gamble Task ---
Huey, E.D. [24] 8 --- RBANS NPI
Kertesz, A. [25] 36 CGI-S, CGI-I WAB, MMSE, DRS FBI, NPI, ADLS
Vercelletto, M. [19] 49 CIBIC+ MMSE, DRS NPI, FBI, DAD, ZBI
Boxer, A.L. [7] 81 CGI-C CVLT, fluency, BNT, Trail Making test,
Digit Backwards, Digit symbol
NPI
Jesso, S. [26] 20 --- Emotion recognition, emotion processing,
Theory of Mind task
NPI, FBI
ADLS, alzheimer’s disease cooperative study—activities of daily living scale; BEHAV-AD, behavioral pathology in alzheimer’s disease rating scale; BNT, Boston
naming test; CBI, Cambridge behavioral inventory; CGI-C, clinical global impression of change; CGI-I, clinical global impression of improvement; CGI-S, clinical
global impression of severity; CIBIC+, clinician’s interview-based impression of change plus caregiver input; CIRS, clinical insight rating scale; CSDD, cornell scale for
depression in dementia; CVLT, California verbal learning test; DAD, disability assessment for dementia; DRS, dementia rating scale, FBI, frontal behavioral inventory;
MMSE, mini mental status exam; NART, National test of adult reading; NPI, neuropsychiatric inventory; RBANS, repeatable battery for the assessment of
neuropsychological status; WAB, Western Aphasia battery; ZBI, Zarit burden inventory.
*(immediate and delayed pattern recognition, spatial recognition, spatial span, spatial working memory, visual discrimination learning/attentional set shifting,
decision-making “gamble,” and paired associates learning).
**(pattern recognition memory, spatial recognition memory, spatial span, spatial working memory, and intradimensional (ID)/extradimensional (ED) attentional-set
shifting, and Tower of London test of spatial planning).
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ventory (NPI) [14] was the most frequently employed,
appearing in eight of nine studies. The extent to which
findings of behavioral improvement across trials is related
to greater uniformity in assessment approaches remains
unclear, though greater consistency would minimize su-
perfluous variance related to methods.
Limitations of the existing literature
Although there are myriad reasons why a trial could fail,
one possible explanation for the lack of significant findings
may relate to the endpoint selection. Within the field of
neuropsychology, there is a relative lack of consensus re-
garding operationalization of cognitive constructs and se-
lection of measures to quantify those constructs, with
many different tests currently being used in research and
clinical applications see [30,31] for review. The result is
that the same construct has been defined and measured in
multiple ways, using different tests that do not necessarily
overlap. One immediate consequence of this variability is
the introduction of unique method variance to outcomes
research due to the use of tests with varying psychometric
properties (e.g., standard error of measurement, reliabil-
ity), which potentially masks treatment effects, inflates
Type I and Type II measurement error, and hinders large-
scale aggregation of data for meta-analytic study. The lack
of evidence for cognitive improvement in a RCT may also
be due to selection of insensitive measures. In the early
phases of the disease, the changes in cognition may be so
subtle that the measures employed lacked adequate sensi-
tivity to small magnitudes of change.One approach to enhancing uniformity and facilitating
use of appropriate measures is to promote convergence
among investigators toward common methods and data
elements (e.g., NIH Toolbox, The Cognitive Atlas, Pa-
tient Reported Outcome Measurement Information Sys-
tem [PROMIS]), particularly for those tools used in
clinical trials. Although the trial performance character-
istics are unknown, the Uniform Data Set (UDS) for
FTLD is one example of a brief cognitive battery that
has been developed and successfully deployed to create
uniformity among assessments at Alzheimer’s Disease
Centers [32]. The NIH EXAMINER is a battery targeting
brief assessment of executive functioning and social cog-
nition, specifically for use in clinical trials. It has shown
promise for the assessment of executive functions
[33,34] and if acceptable performance characteristics in
clinical trials can be demonstrated, its adoption would
facilitate measurement standardization.
What makes a good endpoint?
During the planning phase of a controlled trial, selection
of appropriate measures is crucial, and there are multiple
factors to consider in addition to FDA or EMA require-
ments. Given the potential for small effect sizes, measures
must be able to identify small incremental changes over
time by employing a metric that is fine enough to detect
such changes. For example, using a measure with a binary
metric (e.g., “normal” vs. “impaired”) may be too coarse
and risk missing more subtle degrees of change. It is also
imperative that the measures provide adequate coverage
of the constructs or behaviors of interest, sampling over
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limitations imposed by statistical distributions (i.e., ceiling
and floor effects). Using measures that have a level of diffi-
culty so low that baseline assessments result in a pre-
ponderance of scores falling at or near the ceiling is
inappropriate, as such a distribution of scores allows for
change in only one direction (i.e., decline). Measures
also cannot be so difficult that the distribution of obtained
scores is skewed towards the floor, for similar reasons.
Additionally, by selecting measures with inadequate cover-
age, or too small a range of possible measurements, the
risk of generating skewed data is increased.
Outcome measures should also be suitable for repeat
administration, yet relatively robust to practice effects to
ensure that observed changes reflect true signal variance
and not residual effects due to repeated measurement (i.e.,
practice effects) or poor reliability. The inherent nature of
a randomized controlled trial results in multiple assess-
ments over the course of the trial and there are several
methods to help account for practice effects. Some mea-
sures, however, are more vulnerable than others. For ex-
ample, use of the Wisconsin Card Sorting Test [35], while
useful in some clinical contexts, is particularly susceptible
to practice effects [36,37] and is thus inappropriate for use
in clinical trials as a primary endpoint. While many mea-
sures employ alternate forms, which can be beneficial,
they are not immune to practice effects due procedural fa-
miliarity with the assessment process (e.g., knowing that a
presented word list or visual display is likely subject to
later recall). In addition to careful selection of measures,
practice effects should be accounted for in the methodo-
logical design and statistical analyses. The significance of
practice effects cannot be overstated, as they can signifi-
cantly inflate Type I error rates by masking decline. Using
an unreliable test leads to similar concerns.
In order to increase the potential for widespread adoption
of an endpoint, the trial measures should also be readily
available and easily accessible. Using measures that are diffi-
cult or expensive to obtain, and complicated and lengthy to
administer will limit implementation. Identifying a small set
of measures to be employed across FTD clinical trials will
facilitate synthesis of results, meta-analysis and critical re-
view, fostering development of a stronger evidence-base.
With the increasing prevalence of multinational trials, using
endpoints that have been translated and standardized
across multiple languages is also beneficial where possible.
The Addenbrooke Cognitive Examination, Revised (ACE-
R) [38] and Montreal Cognitive Assessment (MoCA) [39]
for example, have each been translated into several different
languages facilitating international use.
Global measures
As with RCTs for AD, clinical trials in FTD should give
strong consideration for use of a combined measure thatquantifies cognitive, behavioral and functional status in a
single metric in order to increase sensitivity to change,
particularly in the early phases of the disease. The Clin-
ical Dementia Rating – Sum of Box Scores (CDR-SOB)
is one such example that has been used in AD trials and
an extension of the CDR adding two domains specific to
FTD has also been developed (FTD-CDR), which in-
cludes ratings for Language as well as Behavior, Com-
portment and Personality [40]. The FTD-CDR has
demonstrated an association with degree of hypometa-
bolism on fluorodeoxyglucose positron emissions tom-
ography (FDG-PET) studies [41] and demonstrated
sensitivity to change in a mock clinical trial [40]. Simi-
larly, the Clinician Global Impressions scales should also
be considered, as they have already been implemented in
several trials and have documented sensitivity to change
[7]. The ACE-R, which incorporates the MMSE as well
as further assessment of attention, memory, verbal flu-
ency, language and visuospatial function has also shown
sensitivity to change in bvFTD [42].
The CIBIC [4] is another example of a viable measure
which incorporates a caregiver interview (CIBIC+). The
CIBIC + utilizes Likert scales for disease severity and
changes based on observation and written accounts
summarizing semi-structured interviews evaluating be-
havior, cognition, and function and has demonstrated
sensitivity to change in placebo groups [19]. Appropriate
use of the FTD-CDR and CIBIC + relies on the expertise
of the examiner and, as with any interview-based meas-
ure generating ratings on subjective input, being mindful
of the quality and reliability of informant data is import-
ant. Training, clinical trial site quality, turnover of raters,
and other operational details impact the quality of data
collected and must be supervised in a RCT.
The sample size required to show a drug-placebo dif-
ference in a clinical trial depends on the observed rate of
change, the standard deviation of the measure, and the
effect size of the agent. The FTD-CDR changes by ap-
proximately 3.5 pointe per year. Anticipating a small ef-
fect size of disease-modifying agents (e.g., 25% showing),
Knopman et al. (2008) estimated a sample size of 251
for an alpha of 0.05 and power of 80% (for a two arm
trial). Composite scores based on multiple assessments
of executive function or language function shows greater
annual change and smaller sample sizes to demonstrate
a drug benefit [40,43]. Recruiting the required number
of patients will require multiple sites and diligent effort.
Individual measures
For many reasons, a brief screening measure may be a
tempting endpoint. However, selection of an appropriate
measure becomes even more critical when using a brief
measure with fewer items, as a smaller item pool nega-
tively influences reliability and stability of estimates. The
Miller et al. Translational Neurodegeneration 2014, 3:12 Page 5 of 9
http://www.translationalneurodegeneration.com/content/3/1/12MMSE for example, has been used extensively as a
screening tool and secondary outcome in clinical trials
in AD, and has been one of the most frequent cognitive
endpoints used in FTD trials to date. However, the
MMSE lacks executive function measures and relies
heavily on changes in memory to generate an abnormal
score, which may not capture the cognitive changes in
FTD. Not only does the MMSE have inadequate cover-
age of the target domains, it is also highly prone to ceil-
ing effects and utilizes a relatively coarse metric, thus
seriously limiting its appropriateness in a clinical trial
setting. The MoCA may be a better alternative, showing
increased sensitivity to cognitive impairment over the
MMSE [44-46] while retaining a similar level of simpli-
city in both scoring and administration. The MoCA has
demonstrated sensitivity to change over time in a de-
mentia population [47]. The MoCA provides greater as-
sessment of a broader range of cognitive abilities,
including executive functioning and may capture critical
elements of the FTD syndrome. The MoCA has been
validated in multiple languages and has alternate forms
available [48].
Targeted assessment of cognition, particularly language
and executive functioning, may be warranted depending on
the nature of the trial and study population. Assessment of
language functioning is key for trials focusing on the
language-predominant subtypes of FTD (i.e., semantic de-
mentia, progressive non-fluent aphasia). Reliable assess-
ment can be difficult due to the importance of qualitative
changes (e.g., rate, prosody, latency) in language not readily
captured by traditional language measures. In some in-
stances it may be beneficial to generate audio recordings of
participants to allow for multiple ratings of speech and lan-
guage quality; however, quantitative metrics are needed.
Two commonly employed clinical measures of expressive
and receptive language that allow for flexibility in their ad-
ministration and targeting of specific language components
are the Western Aphasia Battery WAB; [49] and the Boston
Diagnostic Aphasia Examination BDAE; [50]. The ACE has
also demonstrated sensitivity to language impairments and
change over time in PNFA and SD [51] and the Boston
Naming Test BNT; [52] has also been widely used. Devel-
opment and validation of novel assessment approaches and
tools for measuring language may be required and advance-
ments in voice recognition software and integration of
technology may prove useful [53].
Given the known changes in frontal systems function-
ing, measuring executive functions should be an integral
component of clinical trials in FTD. Trials in AD have
previously employed trail making tests, fluency esti-
mates, and response inhibition, though many of these
tests are performance-based and vulnerable to practice
effects, which will need to be prospectively addressed in
the experimental design and data analysis. The ExecutiveInterview (EXIT-25) is a brief cognitive screen that em-
phasizes executive function, and has been used in clin-
ical trials in this population [7,54]. A similar executive
screening measure, the Frontal Assessment Battery
(FAB) [55], has been used with some suggestion of su-
periority to the EXIT-25 [56]. The NIH EXAMINER
[33] is another battery developed explicitly as a brief, ef-
ficient method of assessing executive functions for use
in clinical trials, however, multisite assessment and inde-
pendent validation of this approach are needed.
Including assessment of memory is also important,
though perhaps less so in comparison to AD trials where
memory impairment is a primary symptom. If memory
is to be quantified, selection of appropriate endpoints
will require careful consideration, as traditional indices
of memory functioning may be problematic as markers
of cognitive change. Delayed free-recall scores are highly
susceptible to floor effects, while recognition scores are
limited by ceiling effects, particularly early in the phase
of disease when changes are more likely to be very sub-
tle. Alternatively, learning acquisition (i.e., learning over
trials) as a marker of immediate recall, recall-recognition
contrast measures, or recognition discriminability (i.e.,
hits vs. false-positives) may be better outcomes for asses-
sing memory that are readily generated by many verbal
and nonverbal list-learning tasks (e.g., California Verbal
Learning Test, 2nd Ed.; [57]; Hopkins Verbal Learning
Test; [58]).
Composite measures
A potential risk of using multiple individual measures as
the primary or secondary cognitive endpoints is the chal-
lenge of multiplicity, from which it may be difficult to de-
rive meaningful change. Composite scores potentially
address this issue by aggregating results from individual
measures into a single cognitive index; however, use of
composites must be theoretically justified. Creating a
composite score via statistical data reduction methods (e.
g., principal components analysis, factor analysis) may not
be appropriate as it relies on a posteriori knowledge and
capitalizes upon unique variances within the study sample
that may limit generalization of the composites to other
samples. A variant on generating a composite score is use
of a standardized battery that generates both individual
domain scores as well as a global index, which can be im-
plemented across multiple sites using a common norma-
tive reference. In addition to the NIH EXAMINER, the
cognitive subscale of the ADAS-Cog is an example of a
composite battery that has been widely employed in AD
drug trials. As with the MMSE, however, the ADAS-Cog
targets the domains of memory and language and, in order
to be appropriate for use in FTD trials, the expanded ver-
sion, which includes additional assessment of executive
functions, should be used [59]. Experience with this
Table 2 Review of potential endpoints for consideration
Domain Test example Strengths Limitations
Global Clinician Interview Based
Impression of Change
(with caregiver interview)
Evaluates behavior, cognition and functioning;
previously used in clinical trials; demonstrated
sensitivity to change
Relies on subjective data from caregivers
Clinical Dementia Rating FTD-Specific version available; sensitive to change;
association with biomarkers
Reliance on subjective data; lengthy
to administer; coarse metric
Clinical Global Impressions Widely used in existing trials in FTD;
sensitive to change; individual subscales available
Reliance on subjective data
Composite Montreal Cognitive
Assessment
Brief screen; sensitive to change; multicultural;
alternate forms; freely available
Limited use in clinical trials; insufficient coverage




Multi-domain assessment; alternate forms available Inadequate coverage of executive functioning
Dementia Rating Scale,
2nd Ed.
Multi-domain assessment sensitive to presence
of dementia; previously used in clinical trials
Limited assessment of executive functioning;
no alternate form
EXAMINER Developed with FTD in mind; intended for clinical
trials; customizable; specific to executive functioning;
measures social cognition and behavior
Actual trial performance is to be determined
Neuropsychological
Test Battery
Proven trial performance; sensitive to change Relies heavily on memory functioning;
no alternate forms
Executive Trail Making Test Previously used in clinical trials; extensive
normative data; widely used
Limited sensitivity to change in previous trials;
prone to floor effects
Stroop Test Multiple variants available; extensive normative data;
previously used in clinical trials; relatively immune to
ceiling effects
Sensitive to practice effects; interference
conditions may be prone to floor effects
EXIT-25 Previously used in FTD trials Longer and more complicated
administration than comparable alternatives
Frontal Assessment Battery Brief, simple administration; sensitive to
change; multiple language versions
No alternate forms
Clock Drawing Sensitive to executive dysfunction; simple
and brief administration; many variants available




Sensitive to expressive and receptive
language impairments;
Limited use in clinical trials; limited sensitivity
to speech abnormalities; no alternate forms;
prone to ceiling effects
Western Aphasia Battery Sensitive to expressive language impairments;
previous use in clinical trials
limited sensitivity to speech abnormalities;
no alternate forms; prone to ceiling effects
Controlled Oral Word
Association Test
Previously used in trials; sensitive to change Only one well-validated alternate form;
culturally limited
Boston Naming Test Widely used; extensive normative data;
some use in trials
Non-normal distribution of scores;
no alternate forms; culturally limited
Memory California Verbal
Learning Test, 2nd Ed.
Provides multiple estimates of memory (including
learning) and insight into executive functioning
Only one alternate form; lengthy to administer;
Recognition trials vulnerable to ceiling effects
Rey Auditory Verbal
Learning Test
Previously used in clinical trials; provides estimates
of learning, recall and recognition
Recognition trials vulnerable to ceiling effects;
recall trials vulnerable to floor effects
Visuospatial
Functioning
Judgment of Line Orientation Relatively free from practice effects; minimal
demand on motor and language
Vulnerable to ceiling effects;
can be lengthy administration
Figure Copy tests Insights into perception, organization and
executive functioning; multiple forms
Confounded by motor impairment;
scoring can be complex
Behavior Neuropsychiatric
Inventory
Widely used in clinical trials; sensitive to change Not specific to behavioral changes associated
with FTD; large standard variations; Improvements
may be related to increasing apathy
Frontal Behavior Inventory Sensitive to change; employed in existing trials Improvements may be related to increasing apathy
Frontal Systems
Behavior Examination
Allows for intra-individual comparison;
quantification of apathy
Relies on reliable informant
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RBANS are two similar, brief cognitive batteries that have
been used in clinical trials, however, neither provides ad-
equate coverage of the executive domain and would need
to be supplemented with additional measures. Another
example of a composite measure designed and imple-
mented in clinical trials for AD is the Neuropsychological
Test Battery (NTB) [60]. The advantage of the NTB over
other composites used in AD trials is the added focus on
executive functioning and with known performance char-
acteristics in clinical trials [61], it may be a viable endpoint
for use in FTD trials.
Behavioral measures
For trials targeting bvFTD, reliable assessment of behav-
ioral functioning is an essential component. The NPI
and Frontal Behavioral Inventory (FBI) [62,63] have both
been shown to reliably differentiate between FTD sub-
types at baseline [40] and have shown sensitivity to
change over time [26]. In some circumstances, these
measures may need to be supplemented with additional
behavioral assessment tools due to their emphasis on
more “positive” behavioral disturbances (e.g., agitation,
irritability, disinhibition) over “negative” behaviors (e.g.,
apathy, indifference), which are among the core features
of FTD. Including measures that capture more of these
negative behaviors is recommended in order to ensure
that the spectrum of behavioral disturbances is captured.
The Frontal Systems Behavior Scale FrSBE; [64-66] is
another option for quantification of behavioral distur-
bances that yields separate indexes for apathy, disinhib-
ition and executive dysfunction. In addition to assessing
apathy, the FrSBe also allows for intra-individual com-
parisons. A significant limitation with most, if not all,
measures of behavioral disturbance is that they rely on
the accuracy of caregiver reports. Integrating clinician
ratings of behavior can be beneficial, however, these are
restricted to observable behaviors that may not manifest
in clinic and are heavily influenced by caregiver reports.
Development of behavioral assessment methods that
allow for greater objectivity and validation of caregiver
reports may be particularly beneficial.
Conclusions
Although not intended to be a comprehensive, nor ex-
haustive listing, Table 2, provides an overview of tools
that could be considered for FTD trials, describing their
roles, as well as potential strengths and limitations.
Choosing appropriate endpoints for use in clinical trials
is a complex and difficult decision that has direct impli-
cations on potential for success. For trials focusing on
FTD, a principal challenge in choosing the optimal out-
come measures will depend on how heterogeneous the
targeted FTD sample is likely to be in a given trial. Instudies focusing on one primary subtype (e.g., bvFTD),
a primary outcome measure targeting that groups’ main
symptom combined with a global or functional co-
primary may be appropriate. Studies aimed at more het-
erogeneous samples on the other hand, may require out-
comes surveying a broader range of functioning in order
to generate meaningful results. Use of readily available
measures that provide sufficient coverage of the targeted
domain while retaining an adequate sensitivity to change
is critical in order to maximize chances for beneficial out-
comes. Development and application of appropriate trial
outcomes is critically important to success in development
of necessary treatments for FTD patients.
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